Knockdown Of Heme Oxygenase-1 Promotes Apoptosis And Autophagy And Enhances The Cytotoxicity Of Doxorubicin In Breast Cancer Cells

Xiao-Feng Zhu,Wen Li,Jie-Yi Ma,Nan Shao,Yun-Jian Zhang,Rui-Ming Liu,Wei-Bin Wu,Ying Lin,Shen-Ming Wang
DOI: https://doi.org/10.3892/ol.2015.3735
2015-01-01
Oncology Letters
Abstract:Heme oxygenase-1 (HMOX-1) is a microsomal enzyme that exerts anti-apoptotic and cytoprotective effects. In the present study, HMOX-1 was demonstrated to be over-expressed and able to be induced by doxorubicin in breast cancer cell lines. Knockdown of HMOX-1 using short interfering ( si) RNA enhanced the cytotoxicity of doxorubicin in MDA-MB-231 and BT549 cells. Knockdown of HMOX-1 downregulated B cell lymphoma (Bcl)-2 and Bcl-extra large expression, and significantly enhanced doxorubicin-induced apoptosis in MDA-MB-231 and BT549 cells. Additionally, knockdown of HMOX-1 upregulated light chain 3B expression and markedly increased the accumulation of autophagic vacuoles in MDA-MB-231 and BT549 cells treated with doxorubicin. These results indicated that HMOX-1 may be involved in conferring the chemoresistance of breast cancer cells, by preventing apoptosis and autophagy. Therefore, HMOX-1 may represent a potential therapeutic target for enhancing the cytotoxicity and efficacy of doxorubicin during the treatment of breast cancer.
What problem does this paper attempt to address?